Abstract
This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the β-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTA-TOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours.
References
Krenning EP, Bakker WH, Breeman WAP, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.Lancet 1989; 1: 242–244.
Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumours.N Engl J Med 1990; 323: 1246–1249.
Sivolapenko GB, Douli V, Pectasides D, et al. Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody.Lancet 1995; 346: 1662–1666.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Otte, A., Jermann, E., Behe, M. et al. DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24, 792–795 (1997). https://doi.org/10.1007/BF00879669
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00879669